Cara Therapeutics Inc (CARA) Insider Frederique Ph.D. Menzaghi Sells 20,000 Shares

Cara Therapeutics Inc (NASDAQ:CARA) insider Frederique Ph.D. Menzaghi sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $18.65, for a total value of $373,000.00. Following the completion of the sale, the insider now directly owns 139,582 shares in the company, valued at $2,603,204.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Frederique Ph.D. Menzaghi also recently made the following trade(s):

  • On Thursday, February 28th, Frederique Ph.D. Menzaghi sold 1,500 shares of Cara Therapeutics stock. The stock was sold at an average price of $17.50, for a total value of $26,250.00.
  • On Monday, February 25th, Frederique Ph.D. Menzaghi sold 2,200 shares of Cara Therapeutics stock. The stock was sold at an average price of $17.50, for a total value of $38,500.00.
  • On Friday, December 28th, Frederique Ph.D. Menzaghi sold 4,300 shares of Cara Therapeutics stock. The stock was sold at an average price of $12.53, for a total value of $53,879.00.
  • On Friday, December 28th, Frederique Ph.D. Menzaghi sold 4,300 shares of Cara Therapeutics stock. The shares were sold at an average price of $12.53, for a total value of $53,879.00.

CARA stock traded down $0.58 during midday trading on Friday, hitting $18.37. The company’s stock had a trading volume of 1,713,773 shares, compared to its average volume of 676,184. The stock has a market capitalization of $684.83 million, a PE ratio of -8.92 and a beta of 2.68. Cara Therapeutics Inc has a 12 month low of $11.46 and a 12 month high of $24.30.

Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.07. The firm had revenue of $5.53 million for the quarter, compared to the consensus estimate of $3.35 million. As a group, analysts predict that Cara Therapeutics Inc will post -2.31 EPS for the current year.

Several research firms recently issued reports on CARA. Zacks Investment Research raised Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 21st. BidaskClub cut Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 1st. Jefferies Financial Group began coverage on Cara Therapeutics in a research report on Wednesday, February 6th. They issued a “buy” rating and a $22.00 price objective on the stock. Bank of America began coverage on Cara Therapeutics in a research report on Tuesday, January 15th. They issued a “neutral” rating and a $19.00 price objective on the stock. Finally, Janney Montgomery Scott began coverage on Cara Therapeutics in a research report on Thursday, December 20th. They issued a “buy” rating and a $13.36 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. Cara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $24.03.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Avondale Wealth Management lifted its holdings in shares of Cara Therapeutics by 50.0% during the 4th quarter. Avondale Wealth Management now owns 3,000 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Cara Therapeutics by 36.6% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,601 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 964 shares during the period. Captrust Financial Advisors lifted its holdings in shares of Cara Therapeutics by 40.0% during the 4th quarter. Captrust Financial Advisors now owns 4,900 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 1,400 shares during the period. Advisory Services Network LLC lifted its holdings in shares of Cara Therapeutics by 39,086.4% during the 4th quarter. Advisory Services Network LLC now owns 8,621 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 8,599 shares during the period. Finally, NumerixS Investment Technologies Inc bought a new position in shares of Cara Therapeutics during the 4th quarter valued at $121,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was copied illegally and republished in violation of U.S. and international copyright laws. The legal version of this story can be viewed at https://sportsperspectives.com/2019/03/15/cara-therapeutics-inc-cara-insider-frederique-ph-d-menzaghi-sells-20000-shares.html.

About Cara Therapeutics

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Story: Benefits of owning preferred stock

Insider Buying and Selling by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply